Trials / Completed
CompletedNCT00714090
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
Repetitive Transcranial Magnetic Stimulation Efficacy for Major Resistant Depression Compared or Associated With Venlafaxine : a Multicentric Study.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Club rTMS et Psychiatrie · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy of add-on therapy with repetitive Transcranial Magnetic Stimulation (rTMS) and venlafaxine in the treatment of major depressive disorders compared to venlafaxine only (the optimal medication) and to rTMS only.
Detailed description
rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed | active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks. active rTMS : 5 sessions per week for 2 to 6 weeks |
| OTHER | active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine | active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks. |
| OTHER | sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine | sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks. |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2012-07-01
- Completion
- 2013-07-01
- First posted
- 2008-07-14
- Last updated
- 2013-07-19
Locations
18 sites across 2 countries: France, Monaco
Source: ClinicalTrials.gov record NCT00714090. Inclusion in this directory is not an endorsement.